Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BGT226 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| BGT226 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BGT226 | DRUG | - |
Inclusion criteria: All patients * Histologically-confirmed, advanced solid tumors * Progressive, recurrent unresectable disease Phase II expansion part (advanced breast cancer) * Confirmed positive hormone receptor (estrogen receptor and/or progesterone receptor) or positive HER-2 expression st...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BGT226 is an investigational small molecule drug developed by Novartis AG for the treatment of advanced solid tumors. It was studied in a Phase 1/2 clinical trial that enrolled 57 adult patients with advanced solid malignancies, including advanced breast cancer and Cowden syndrome. It is not an approved therapy and remains in clinical development.
BGT226 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. It targets the PIK3CA, PIK3CB, PIK3CD, and PIK3CG catalytic subunits as well as the PIK3R1 and PIK3R2 regulatory subunits. By inhibiting these PI3K proteins, BGT226 interferes with signaling pathways involved in tumor cell growth and survival.
BGT226 is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis sponsored the Phase 1/2 study of the compound in patients with advanced solid malignancies.
BGT226 is in Phase 1 development. It has been evaluated in a single Phase 1/2 clinical trial in adult patients with advanced solid malignancies. The trial is completed, and no active trials of BGT226 are currently listed. The drug is investigational and has not been approved by the FDA.
BGT226 was studied in clinical trial NCT00600275, titled a Phase I/II study of BGT226 in adult patients with advanced solid malignancies, including patients with advanced breast cancer. The trial enrolled 57 patients across the United States, Canada, and Spain, and it is now completed.
BGT226 was studied for the treatment of advanced solid tumors, including advanced breast cancer and Cowden syndrome, in adult patients aged 18 years and older. The Phase 1/2 trial NCT00600275 evaluated the drug in this patient population and has been completed.